title: The levonorgestrel intrauterine system (Mirena) for treatment of idiopathic menorrhagia. Assessment of quality of life and satisfaction.
abstract: OBJECTIVE
  To evaluate patient satisfaction and improvement in quality of life (QoL) among women with idiopathic menorrhagia treated with the levonorgestrel intrauterine system (LNG-IUS).
  
  
  METHODS
  Prospective-observational study with one-year follow-up in which 225 women were enrolled who had a LNG-IUS inserted for control of idiopathic menorrhagia. Bleeding, tolerability, user satisfaction, and health-related QoL (by means of the SF-36 QoL questionnaire) were assessed.
  
  
  RESULTS
  There was a statistically significant reduction in the amount of bleeding, an increase of haemoglobin and ferritin levels, and an improved QoL score. A high degree of satisfaction was reported by over 98% of patients.
  
  
  CONCLUSIONS
  The LNG-IUS is an effective and well-tolerated treatment modality in idiopathic menorrhagia. The QoL of women treated with the LNG-IUS is markedly improved, causing high levels of patient satisfaction. This IUS can be regarded as a first-choice therapy in idiopathic menorrhagia.
authors.affiliation: Santiago Apostol Hospital, Vitoria, Alava, Spain. ilete@hsan.osakidetza.net
authors.forename: I
authors.initials: I
authors.lastname: Lete
authors.forename: C
authors.initials: C
authors.lastname: Obispo
authors.forename: F
authors.initials: F
authors.lastname: Izaguirre
authors.forename: T
authors.initials: T
authors.lastname: Orte
authors.forename: B
authors.initials: B
authors.lastname: Rivero
authors.forename: M J
authors.initials: MJ
authors.lastname: Cornellana
authors.forename: I
authors.initials: I
authors.lastname: Bermejo
mesh_terms: D000328:Adult; D003271:Contraceptive Agents, Female / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005293:Ferritins / Q000097:blood; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel / Q000009:adverse effects / Q000627:therapeutic use*; D008595:Menorrhagia / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D017060:Patient Satisfaction; D011446:Prospective Studies; D011788:Quality of Life; D018434:Sickness Impact Profile; D013030:Spain
chemical_list: D003271:Contraceptive Agents, Female; D006454:Hemoglobins; D016912:Levonorgestrel; D005293:Ferritins